RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Radiation Injuries
Accession: DOID:9000111
browse the term
Definition: Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.
Synonyms: exact_synonym: Radiation Injury; Radiation Sickness; Radiation Sicknesses; Radiation Syndrome; Radiation Syndromes
primary_id: MESH:D011832 ; RDO:0001778
For additional species annotation, visit the
Alliance of Genome Resources .
G
Bdnf
brain-derived neurotrophic factor
treatment
IEP
RGD
PMID:24333433
RGD:10059359
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
G
Csf2
colony stimulating factor 2
ISO
mRNA:increased expression:bone marrow,spleen:
RGD
PMID:7662961
RGD:10449513
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
G
Hif1a
hypoxia inducible factor 1 subunit alpha
treatment
ISO
RGD
PMID:17340073
RGD:8695920
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
G
Il1a
interleukin 1 alpha
IEP
RGD
PMID:7938676
RGD:7794763
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
G
Mir122
microRNA 122
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:32422326
NCBI chr18:60,755,285...60,755,369
G
Sod2
superoxide dismutase 2
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:16540396 PMID:21945096
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
G
Tgfbr2
transforming growth factor, beta receptor 2
IDA
RGD
PMID:12957270
RGD:1601599
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
G
Abcb1a
ATP binding cassette subfamily B member 1A
susceptibility
ISO
DNA:missense mutation:cds:p.G671V (human)
RGD
PMID:16330681
RGD:11041175
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
G
Capn2
calpain 2
treatment
IEP
RGD
PMID:25634181
RGD:13792617
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
G
Ercc2
ERCC excision repair 2, TFIIH core complex helicase subunit
ISO
associated with Leukemia, Myeloid, Acute;DNA:SNP:exon:p.K751Q (rs13181) (human)
RGD
PMID:24284041
RGD:11252190
NCBI chr 1:80,293,574...80,307,334
Ensembl chr 1:80,293,566...80,307,344
G
Bche
butyrylcholinesterase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:26145887
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
G
Bmp2
bone morphogenetic protein 2
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:29800642
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
G
Ccl2
C-C motif chemokine ligand 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:29959987
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
G
Csf1
colony stimulating factor 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:32068018
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
G
Hbegf
heparin-binding EGF-like growth factor
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:29305325
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
G
Il1b
interleukin 1 beta
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:32068018
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
G
Mir208a
microRNA 208a
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:26454886
NCBI chr15:33,613,451...33,613,533
G
Nos3
nitric oxide synthase 3
treatment
ISO
associated with Precursor Cell Lymphoblastic Leukemia-Lymphoma;DNA:polymorphism: :894G>T(human)
RGD
PMID:26345518
RGD:11533645
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
G
Nppb
natriuretic peptide B
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:29959987
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
G
Nrg1
neuregulin 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:29305325
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
G
Rac1
Rac family small GTPase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:28710503
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
G
Rarg
retinoic acid receptor, gamma
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:26237429
NCBI chr 7:143,840,739...143,863,206
Ensembl chr 7:143,839,980...143,863,186
G
Tlr2
toll-like receptor 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:29959987
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
G
Tnf
tumor necrosis factor
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:29959987 PMID:32068018
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
G
Tp53
tumor protein p53
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:30009776
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
G
Cd274
CD274 molecule
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:28736328
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
G
Cebpa
CCAAT/enhancer binding protein alpha
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:21346772
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
G
Agtr1a
angiotensin II receptor, type 1a
IMP
RGD
PMID:14982483
RGD:6903857
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
G
Agtr2
angiotensin II receptor, type 2
IMP
RGD
PMID:14982483
RGD:6903857
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
G
Aif1
allograft inflammatory factor 1
IEP
protein:decreased expression:brain (rat)
RGD
PMID:19070908
RGD:2313024
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
G
Casp3
caspase 3
treatment
IEP
RGD
PMID:24939579
RGD:13782350
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
G
Casp8
caspase 8
treatment
IEP
RGD
PMID:24939579
RGD:13782350
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
G
Casp9
caspase 9
treatment
IEP
RGD
PMID:24939579
RGD:13782350
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
G
Ccn2
cellular communication network factor 2
IEP
protein:increased expression:kidney (rat)
RGD
PMID:19080126
RGD:2314603
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
G
Eng
endoglin
ISO IEP
kidney protein:decreased expression:lung (rat)
RGD
PMID:23022174 , PMID:22151990
RGD:7248771 , RGD:7257525
NCBI chr 3:11,679,530...11,717,486
Ensembl chr 3:11,679,530...11,717,485
G
Fas
Fas cell surface death receptor
IEP
mRNA:increased expression:testis (rat)
RGD
PMID:9927315
RGD:8662886
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
G
Hif1a
hypoxia inducible factor 1 subunit alpha
IEP ISO
protein:increased expression:white matter of spinal cord (rat) CTD Direct Evidence: therapeutic
CTD
PMID:23065176 , PMID:15161688
RGD:9068912
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
G
Hmox1
heme oxygenase 1
treatment
IMP
RGD
PMID:22247972
RGD:10755582
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
G
Ifng
interferon gamma
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11121210
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
G
Igf2
insulin-like growth factor 2
IEP
mRNA:increased expression:brain
RGD
PMID:11213353
RGD:5509971
NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
G
Il10
interleukin 10
treatment
IDA IEP
protein:increased expression:plasma
RGD
PMID:23788042 , PMID:23968122
RGD:7365012 , RGD:11049496
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
G
Il18
interleukin 18
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11121210
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
G
Il1b
interleukin 1 beta
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11121210
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
G
Mapk1
mitogen activated protein kinase 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:22247605
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
G
Mapk3
mitogen activated protein kinase 3
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:22247605
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
G
Mir122
microRNA 122
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:32422326
NCBI chr18:60,755,285...60,755,369
G
Nos1
nitric oxide synthase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20726721
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
G
Pcna
proliferating cell nuclear antigen
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:21931560
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
G
Pecam1
platelet and endothelial cell adhesion molecule 1
IEP
mRNA:altered expression:jejunum, duodenum, ileum (rat)
RGD
PMID:22227376
RGD:6767294
NCBI chr10:94,850,971...94,913,202
G
Ptgs1
prostaglandin-endoperoxide synthase 1
IEP
protein:increased expression:intestine
RGD
PMID:17699727
RGD:2290567
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
G
Ptgs2
prostaglandin-endoperoxide synthase 2
IEP
protein:increased expression:intestine
RGD
PMID:17699727
RGD:2290567
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
G
Sod1
superoxide dismutase 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:22247605
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
G
Sod2
superoxide dismutase 2
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:11121210 PMID:20726721
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
G
Tnf
tumor necrosis factor
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11121210
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
G
Ace
angiotensin I converting enzyme
treatment
IMP
RGD
PMID:8995730
RGD:12880012
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
G
Serpine1
serpin family E member 1
treatment
IEP
RGD
PMID:8995730
RGD:12880012
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
G
Alox5
arachidonate 5-lipoxygenase
IMP
RGD
PMID:1886988
RGD:4890434
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
G
C3
complement C3
ISO
Protein: increased expression: plasma
RGD
PMID:20510197
RGD:5129484
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
G
C4bpa
complement component 4 binding protein, alpha
ISO
Protein: increased expression: plasma
RGD
PMID:20510197
RGD:5129484
NCBI chr13:47,342,090...47,377,580
Ensembl chr13:47,342,079...47,377,703
G
Ccl17
C-C motif chemokine ligand 17
IEP
mRNA, protein:increased expression:lung, alveolar macrophage
RGD
PMID:15293604
RGD:4145517
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
G
Ccl22
C-C motif chemokine ligand 22
IEP
mRNA, protein:increased expression:lung, alveolar macrophage
RGD
PMID:15293604
RGD:4145517
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
G
Il13
interleukin 13
susceptibility
ISO
associated with carcinoma, non-small-cell lung; DNA:SNPs: :rs20541, rs180925 (human)
RGD
PMID:20811626
RGD:5131286
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
G
Il1a
interleukin 1 alpha
susceptibility
ISO
associated with carcinoma, non-small-cell lung: DNA:SNPs: :rs1800587,rs17561(human)
RGD
PMID:20811626
RGD:5131286
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
G
Mif
macrophage migration inhibitory factor
susceptibility
ISO
associated with carcinoma, non-small-cell lung; DNA:SNP: :rs755622(human)
RGD
PMID:20811626
RGD:5131286
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
G
Nos3
nitric oxide synthase 3
susceptibility
ISO
associated with carcinoma, non-small-cell lung;DNA:SNP:cds:c.894G>T rs1799983 (human)
RGD
PMID:20811626
RGD:5131286
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
G
Sftpd
surfactant protein D
susceptibility
ISO
RGD
PMID:20459699
RGD:4143486
NCBI chr16:18,753,535...18,766,100
Ensembl chr16:18,745,458...18,766,174
G
Tgfb1
transforming growth factor, beta 1
susceptibility
ISO IMP
protein:increased expression:blood DNA:SNP:exon:869T>C (rs1982073) (human)
RGD
PMID:19943923 , PMID:18411002 , PMID:19380441
RGD:4145121 , RGD:4145278 , RGD:4145136
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
G
Tnf
tumor necrosis factor
susceptibility
ISO
associated with carcinoma, non-small-cell lung: DNA:SNPs: :rs1799724(human)
RGD
PMID:20811626
RGD:5131286
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
G
Tnfrsf1a
TNF receptor superfamily member 1A
ISO
RGD
PMID:18347190
RGD:5131153
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
G
Vtn
vitronectin
ISO
Protein: increased expression: plasma
RGD
PMID:20510197
RGD:5129484
NCBI chr10:65,767,960...65,771,040
Ensembl chr10:65,767,053...65,771,038
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all